Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELARA open-label extension study of OV101 in Angelman syndrome
MOH_2019-01-31_005936Phase 2Not yet recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gaboxadol in Angelman syndrome (AS), sponsored by Ovid Therapeutics. Primary endpoint: Long-term safety and tolerability of OV101. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on MOH_2019-01-31_005936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-31_005936.